CareTalk: Healthcare. Unfiltered. Episode #82 - Obamacare to Bidencare: What's Next with Dan Mendelson
Founder and former CEO of Avalere Health, Dan Mendelson, stops by to share his outlook on Bidencare and the future of health policy in the US.
About Dan Mendelson:
Dan Mendelson is Founder and former CEO of Avalere Health, a vibrant community of innovative thinkers dedicated to solving the challenges of the healthcare system.
He is also Operating Partner at Welsh Carson, a private equity firm focused on healthcare and technology investments. Prior to founding Avalere in 2000, Dan served as Associate Director for Health at the Office of Management and Budget in the Clinton White House where he was responsible for the full healthcare portfolio including Medicare, Medicaid, NIH, CDC, and FDA.
Dan presently serves on the boards of Champions Oncology (CSBR), Centrexion Corporation, and Audacious Inquiry. He is Adjunct Professor at Georgetown University’s McDonough School of Business, and a founding member of Guidon Partners, an investment management group. Dan also serves on advisory boards for the Alliance for Health Policy, the Duke Margolis Center, and Faster Cures. He previously served on the boards of Coventry Healthcare (CVTY, sold to Aetna in 2013), PharMerica (PMC, sold to KKR in 2017), and HMS holdings (HMSY).
Dan is a leading national thought leader on healthcare business issues, is often quoted in the press, and enjoys speaking. He has also published widely in peer-reviewed and professional journals on health information technology, the costs of disease, hospital costs and operations, physician payment, the economics of managed care, and medical malpractice. He holds a BA from Oberlin College, and an MPP from the Kennedy School at Harvard University.
Watch this episode on YouTube: https://youtu.be/QWKdKhwAICw
#danmendelson #medicare #medicareadvantage #healthinsurance #healthcare #healthcarebusiness #healthcarepolicy
⚙️CareTalk: Healthcare. Unfiltered. is produced by Grippi Media Digital Marketing Consulting.